Articles and Resources

Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity

This study is currently recruiting participants.

Verified by Memorial Sloan-Kettering Cancer Center, June 2010
First Received: December 2, 2009
Last Updated: June 22, 2010
Sponsor: Memorial Sloan-Kettering Cancer Center
Collaborator: Novartis Pharmaceuticals
Information provided by: Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT01024946
Purpose

For patients with malignant pleural mesothelioma that has grown despite treatment with standard chemotherapy, no treatment has yet proven beneficial. The purpose of this study is to find out what effects, both good and bad, that everolimus has on the cancer. Everolimus works by blocking a protein that helps the cancer grow. The goal of this clinical research study is to learn if the study drug everolimus can shrink or slow the growth of mesothelioma. The safety of this drug will also be studied. The patients’ physical state, changes in the size of the tumor, and laboratory findings taken during the study will help us decide if everolimus is safe and effective.

Condition Intervention Phase
Malignant Pleural Mesothelioma Drug: everolimus Phase II
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study
Official Title: Phase II Study of Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Resource links provided by NLM:
Genetics Home Reference related topics:
neurofibromatosis type 2
MedlinePlus related topics:
Cancer
Mesothelioma
Drug Information available for:
Everolimus
U.S. FDA Resources
Further study details as provided by Memorial Sloan-Kettering Cancer Center:
Primary Outcome Measures:
  • To determine the rate of clinical benefit (i.e. rate of complete or partial response plus stable disease) at 16 weeks for patients with malignant mesothelioma treated with everolimus as second or third line therapy. [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
  • To determine the response rate, time to progression and overall survival for patients with mesothelioma treated with everolimus. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • To determine the toxicities of everolimus in this patient population. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • To explore whether or not Merlin/NF2 loss can be used as a biomarker to predict sensitivity to everolimus. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • To determine the relationship between response to treatment and the levels of soluble mesothelin-related peptide (SMRP) and osteopontin. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Estimated Enrollment: 39
Study Start Date: December 2009
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Pts getting everolimus: Experimental
This is a single institution, open label, phase II study of everolimus as a second or third line therapy for the treatment of advanced malignant pleural mesothelioma, which will also evaluate Merlin/NF2 loss as a biomarker to predict sensitivity to everolimus. Patients who have disease progression after one or two prior chemotherapy regimens will be eligible. In the first stage of this design, 19 patients will be accrued. If 6 or less patients among the first 19 patients show clinical benefit, then the study will be terminated and declared negative. If 7 or more patients show clinical benefit, than an additional 20 patients will be accrued to the second stage. At the end of the study, if 17 or more patients show clinical benefit out of a total of 39 patients enrolled, the regimen will be considered worthy of further investigation.
Drug: everolimus
Everolimus will be administered at a dose of 10mg orally once daily continuously. Dose reduction may be required depending on the type and severity of toxicity encountered. One cycle will be considered 28 days. Patients will have CT scans to evaluate for response after cycle 1 and cycle 2, and then every two cycles thereafter.

Eligibility
Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

  • Patients must have a histologically confirmed diagnosis of epithelioid, sarcomatoid, or mixed-type malignant pleural mesothelioma that is not amenable to surgery.
  • Patients must have measurable disease according to the modified RECIST criteria for mesothelioma.
  • Patients must have adequate tissue sample available for analysis of NF2/Merlin loss. (archived tissue block or 10 unstained slides)
  • Patients must have received no more than two prior systemic therapy regimens, and at least one of the regimens must have included pemetrexed.
  • Patients must be at least 18 years of age.
  • Karnofsky performance status > or = to 70%.
  • Adequate renal function: serum creatinine ≤ 1.5 x ULN.
  • Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fasting triglycerides ≤ 2.5 x ULN. NOTE: In case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication.
  • Signed informed consent
  • Patients must have adequate hepatic function as defined by:

    • AST and ALT ≤ 2.5 x ULN (≤ 5x ULN in patients with liver metastases)
    • Serum bilirubin ≤ 1.5 x ULN
  • Patients must have adequate bone marrow function as defined by:

    • Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
    • Platelets ≥ 100 x 109/L
    • Hemoglobin ≥ 9 g/dL

Exclusion Criteria:

  • Patient has been previously treated with an mTOR inhibitor (sirolimus, temsirolimus, or everolimus).
  • Patients currently receiving anticancer therapies or who have received anticancer therapies within 3 weeks of the start of study drug (including chemotherapy, radiation therapy, antibody-based therapy, etc.)
  • Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
  • Prior treatment with any investigational drug within the preceding 4 weeks
  • Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent. Topical or inhaled corticosteroids are allowed
  • Patients should not receive immunization with attenuated live vaccines within one week of study entry.
  • Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:

    • Symptomatic congestive heart failure of New York heart Association Class III or IV
    • unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months of start of study drug, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease
    • uncontrolled diabetes as defined by fasting serum glucose > or = to 1.5 x ULN
  • Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
  • Severely impaired lung function as evidenced by:

    o Spirometry and/or DLCO that is ≤ 50% of the normal predicted value and/or O2 saturation that is ≤ 88% at rest on room air

  • A known history of HIV seropositivity
  • Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)
  • Patients with an active, bleeding diathesis
  • Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes. Hormonal contraceptives are not acceptable as a sole method of contraception. (Women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of everolimus)
  • Patient has an active infection for which they received IV antibiotic, antiviral, or antifungal medications within 2 weeks of starting study drug.
  • Patients with a “currently active” second malignancy.
Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01024946

Contacts
Contact: Lee Krug, MD 212-639-8420


Locations
United States, New York
Memorial Sloan-Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Lee Krug, MD     212-639-8420
Contact: Christopher Azzoli, MD     212-639-2131
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
Novartis Pharmaceuticals
Investigators
Principal Investigator: Lee Krug, MD Memorial Sloan-Kettering Cancer Center
More Information
Responsible Party: Memorial Sloan-Kettering Cancer Center ( Lee Krug M.D )
Study ID Numbers: 09-142
Study First Received: December 2, 2009
Last Updated: December 11, 2009
ClinicalTrials.gov Identifier: NCT01024946

title=”Historical versions of study NCT01024946 on ClinicalTrials.gov Archive Site”
onclick=”openNewWindow(’/ct2/archive/NCT01024946′); return false;”>History of Changes
Health Authority: United States: Institutional Review Board

Keywords provided by Memorial Sloan-Kettering Cancer Center:

mesothelioma

pleural
RAD001

Everolimus

09-142

thoracic

lung
epithelioid

sarcomatoid


Additional relevant MeSH terms:

Mesothelioma

Everolimus

Neoplasms
Neoplasms by Histologic Type

Immunologic Factors

Neoplasms, Mesothelial

Physiological Effects of Drugs

Immunosuppressive Agents
Adenoma

Pharmacologic Actions

Neoplasms, Glandular and Epithelial

ClinicalTrials.gov processed this record on August 23, 2010

Source: http://www.clinicaltrials.gov


Source: www.ClinicalTrials.gov